On December 14, 2016, the U.S. Food and Drug Administration approved Eucrisa (Crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older. The structure of Crisaborole is given below:
Anacor Pharmaceuticals (acquired by Pfizer) is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics.
Anacor’s first approved product, KERYDIN® (tavaborole) topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of onychomycosis of the toenails. Tavaborole and Crisaborole are structural analogs.
Crisaborole (AN2728) is patented in US 8,039,451 B2 which is set to expire on June 11, 2026 (including PTA). However, the term may extended due to Patent term extension.